News | January 7, 2020

Principia Announces Expanded Development Program to Broaden BTK Footprint in Immune-Mediated Diseases Company’s lead candidate PRN1008 receives generic name — rilzabrutinib Rilzabrutinib to enter clinical trial in IgG4-Related Disease SOUTH SAN FRANCISCO,...